Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2014-03-12 AGM Information
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
AGM Information 2014
AGM Information Classification · 99% confidence The document explicitly states it contains information from the 'annual general meeting held on 12 March 2014' and details the resolutions transacted, such as the re-election of board members, adoption of the annual report, declaration of dividend, and approval of remuneration. This content directly corresponds to the materials presented or discussed during an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length (2529 chars) is not indicative of a short announcement (RPA/RNS) but rather a summary of the meeting's outcomes.
2014-03-12 English
AGM Information 2014
AGM Information Classification · 99% confidence The document is titled "Selskabsmeddelelse nr. 11/2014" (Company Announcement No. 11/2014) and explicitly states that the Annual General Meeting (AGM) of ALK-Abelló A/S was held on March 12, 2014. The content details the resolutions passed during this meeting, including the approval of the 2013 annual report, dividend declaration, board elections, and authorization for share repurchases. Since the document reports the outcomes and decisions made at the AGM, it directly relates to AGM Information. The code AGM-R is the most appropriate classification.
2014-03-12 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a press release dated March 10, 2014, announcing positive Phase II/III trial results for an allergy immunotherapy tablet developed by ALK and its Japanese partner, Torii Pharmaceutical. It details efficacy endpoints, safety profiles, and future plans (NDA submission). This content is characteristic of an initial announcement of clinical trial progress, which is typically disseminated via an Earnings Release (ER) or a general Regulatory Filing (RNS) if no other specific category fits. Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a formal legal notice (LTR), and it is announcing a significant business/clinical development, it best fits the 'Earnings Release' category (ER) as it pertains to key operational and clinical milestones that impact future performance, or 'Regulatory Filing' (RNS) as a general announcement. Given the focus on trial results and partnership progress, ER is a strong candidate, but since it's not explicitly tied to a quarterly earnings period announcement, RNS (Regulatory Filings) serves as a safe, broad category for significant, non-standard operational news releases. However, in many financial databases, significant clinical trial updates that are not part of a formal earnings release are often categorized under general regulatory announcements or sometimes Investor Presentations if they were presented as such. Since this is a press release announcing results, and it doesn't fit the specific definitions for LTR, MANG, or CAP, RNS is the most appropriate fallback for a significant, non-financial-statement-related announcement. Given the context of reporting clinical trial success, it is a material event announcement.
2014-03-10 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a press release dated March 10, 2014, announcing positive Phase II/III study results for an allergy treatment developed by ALK and its Japanese partner, Torii Pharmaceutical. It details clinical trial outcomes, quotes the CEO, and provides background information on both companies and their partnership. This type of announcement, focusing on clinical trial results and strategic progress, is typically classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific clinical/partnership update, it fits best under a general regulatory announcement or a specific category if available. Given the options, it is not a formal financial report (10-K, IR, MRQ), nor is it a management presentation (IP) or a call transcript (CT). It is an announcement of significant business/clinical progress. Since it is a formal announcement of a major development (positive study results leading to potential market launch), it is most closely aligned with an Earnings Release (ER) which often includes operational highlights, or, if it's purely non-financial news, the Regulatory Filings (RNS) fallback. However, clinical trial results announcements often accompany or substitute for standard earnings highlights. Given the content is a major operational/clinical milestone announcement, and not a formal financial statement, RNS is the safest general regulatory filing category, but ER often covers key operational achievements. Since this is a specific clinical trial result announcement, and not a general regulatory filing (RNS) or a formal financial report, and it is not about management changes (MANG) or capital (CAP), I will classify it as a Regulatory Filing (RNS) as it is a formal announcement of material information that doesn't fit the other specific categories like ER (which usually focuses on revenue/profit). However, upon re-evaluation, many clinical trial updates are treated as material news announcements, which often fall under RNS or ER if they are significant enough to impact investor outlook. Given the structure and content (press release format, material news), RNS is the most appropriate catch-all for significant, non-standard reports.
2014-03-10 Danish
Report Publication Announcement 2014
Report Publication Announcement Classification · 98% confidence The document is a short announcement from ALK regarding new data presented by its partner, Merck, at an allergy conference. The text explicitly states, "Merck has issued a news release concerning the findings from the clinical trial. The release is enclosed in full length on the following pages." This structure—a brief summary followed by the indication that the full content (likely the partner's release) is attached or follows—fits the definition of a Report Publication Announcement (RPA). It is not the full clinical trial report itself, nor is it a standard regulatory filing like a 10-K or IR. Given the short length (3268 chars) and the nature of announcing the availability of another party's release, RPA is the most appropriate classification based on Rule 2.
2014-03-04 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a press release from ALK announcing that its partner, Merck, presented new clinical trial data for an allergy tablet vaccine at the AAAAI annual meeting. The text explicitly states that 'Merck har offentliggjort en presse­meddelelse om resultaterne fra det kliniske studie. Pressemeddelelsen findes i sin fulde længde på de efterfølgende sider.' This indicates the document itself is an announcement summarizing external news (clinical data presentation) and referencing the full press release. Given the content focuses on clinical trial results and partnership updates, it is not a standard regulatory filing like 10-K or IR. It is a general corporate announcement regarding business/research progress. Since it is a press release announcing results/updates, and it doesn't fit perfectly into ER (Earnings Release) or LTR (Legal Proceedings), the most appropriate general category for corporate news announcements that aren't strictly financial results or management changes is Regulatory Filings (RNS) as a broad announcement category, or potentially a specialized category if one existed for clinical trial updates. However, based on the provided definitions, RNS serves as the best general regulatory/corporate announcement fallback when specific categories like ER or MANG do not apply. The document length (3282 chars) is short, suggesting it is an announcement rather than a comprehensive report.
2014-03-04 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.